WOONSOCKET – With a high-cost cholesterol lowering drug known as a PCSK9 inhibitor newly on the market, CVS Health Research Institute experts are encouraging the cardiology community to reconsider treatment guidelines for the management of high cholesterol.
“The current cholesterol management guidelines do not provide clarity as to how these expensive new medications could fit in the treatment paradigm,” said Dr. William Shrank, chief scientific officer at CVS Health.
In 2013, guidelines produced by the American College of Cardiology and American Heart Association said that physicians should no longer treat patients to a specific cholesterol target but instead pursue a more aggressive management of cholesterol with high-potency medications.
